pharma · Diphtheria · Diabetes Mellitus, Type 2
Sanofi Pasteur MSD
Sanofi Pasteur
Sanofi Pasteur is a pharma organization headquartered in LYON, FR. Primary therapeutic focus areas include Diphtheria, Diabetes Mellitus, Type 2, Japanese Encephalitis, Rabies, Hemophilia A. NovaPharmaNews links 83 clini
Company details
- Status
- Public
- HQ
- France, LYON
- Employees
- 363
- Programs
- 83
- Drugs
- 66
- Patents
- 0
MEQ00074
Phase 3 · mab · Meningococcal Infection
MEQ00074 for Meningococcal Infection is a Phase 3 program (mab) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Internal code MEQ00074
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi Pasteur
- Phase
- Phase 3
- Modality
- mab
- Indication
- Meningococcal Infection
- Status
- completed
- Trials
- 1